Get started
Author

Roberto Andrés Escala Cornejo

Observed names: Escala Cornejo, Roberto Andrés, R. Escala, R.A. Escala Cornejo, Roberto A. Escala Cornejo, Roberto A. Escala-Cornejo, Roberto Escala, Roberto Escala Cornejo, Roberto Escala-Cornejo
Observed institutions: Universidad de Salamanca, Catholic University of Ávila, Universidad Católica de Santiago de Guayaquil, Bristol-Myers Squibb (United States), Complejo Hospitalario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Sociedad de Lucha Contra el Cáncer del Ecuador
ORCID: 0000-0002-6145-7683
Observed ORCID: 0000-0002-6145-7683
OpenAlex ID: A5022658462
Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis
2022 · Alejandro Olivares-Hernández, Edel del Barco Morillo, et al. · Biomedicines · 31
PDF
Renal Cell Carcinoma Associated With Xp11.2 Translocation/TFE3 Gene-fusion: A Long Response to mammalian target of rapamycin (mTOR) Inhibitors
2018 · Oliver R. Rua Fernández, Roberto Escala Cornejo, et al. · Urology · 20
Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors
2021 · Alejandro Olivares-Hernández, Luis Figuero-Pérez, et al. · Case Reports in Oncological Medicine · 18
PDF
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab
2020 · Luis Figuero-Pérez, Alejandro Olivares-Hernández, et al. · Reumatología Clínica (English Edition) · 16
PDF
Large cell neuroendocrine carcinoma of the lung with atypical evolution and a remarkable response to lutetium Lu 177 dotatate
2018 · Roberto A. Escala Cornejo, Paloma García-Talavera, et al. · Annals of Nuclear Medicine · 12
Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy
2022 · Alejandro Olivares-Hernández, Edel del Barco Morillo, et al. · Frontiers in Bioscience-Landmark · 11
Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab
2020 · Luis Figuero-Pérez, Alejandro Olivares-Hernández, et al. · Reumatología Clínica · 8
PDF
Management of Febrile Neutropenia Associated With SARS-CoV-2 Infection in a Patient With Cancer
2020 · Luis Figuero-Pérez, Alejandro Olivares-Hernández, et al. · JCO Oncology Practice · 7
Increased Quality of Life in Patients with Breakthrough Cancer Pain after Individualized Therapy: the CAVIDIOM Study
2022 · Paula González Villarroel, Josep Gumà Padró, et al. · Future Oncology · 5
Identifying the Best Ki-67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification
2022 · Roberto Escala-Cornejo, Alejandro Olivares-Hernández, et al. · EMJ Oncology · 5
PDF
215P Identifying the best Ki67 cut-off for determining luminal breast cancer subtypes using immunohistochemical analysis and PAM50 genomic classification
2020 · R.A. Escala Cornejo, M. Muñoz García, et al. · Annals of Oncology · 5
PDF
Sobrepeso y obesidad como factores predisponentes de hipertensión arterial en niños de 5 a 12 años en Guayaquil y Nobol
2011 · Roberto Escala Cornejo, Katya Barberán Solórzano, et al. · Medicina · 4
PDF
Uso de anakinra en el tratamiento de la infección respiratoria grave por SARS-CoV-2
2022 · Luis Figuero-Pérez, Alejandro Olivares-Hernández, et al. · Reumatología Clínica · 2
PDF
Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infection
2022 · Luis Figuero-Pérez, Alejandro Olivares-Hernández, et al. · Reumatología Clínica (English Edition) · 1
PDF
Reply to A. Lasagna et al
2020 · Luis Figuero-Pérez, Alejandro Olivares-Hernández, et al. · JCO Oncology Practice · 1
PDF
Severe Ketoacidosis as the First Clinical Manifestation of Type 1 Diabetes Mellitus Secondary to Immune Checkpoint Inhibitors
2020 · Alejandro Olivares-Hernández, Roberto A. Escala-Cornejo, et al. · Asian Journal of Oncology · 1
PDF
Determination of anti-pancreatic islet cell antibodies for the prevention of type 1 diabetes mellitus as an immune-related adverse event secondary to treatment with immune checkpoint inhibitors
2019 · A. Olivares Hernández, R.A. Escala Cornejo, et al. · Annals of Oncology · 1
Abstract PS3-10-19: Prevalence of HER2-low status in Ecuadorian women with Hormone Receptor Positive Breast Cancer
2026 · L. Estrada, W. Morquecho, et al. · Clinical Cancer Research
Innovación y equidad en cáncer de mama: ¿HER2-low, oportunidad real o espejismo para países de ingresos medios y bajos?
2025 · Roberto A. Escala Cornejo · Oncología (Ecuador)
PDF
3188eP Estimation of the prevalence of HER2-low breast cancer in south American population: Results from an Ecuadorian cancer center
2025 · W. Morquecho, L. Estrada, et al. · Annals of Oncology
Prognostic value of O6-methylguanine-DNA methyltransferase (MGMT) status in pancreatic neuroendrocrine tumors with capecitabine and temozolomide (CAPTEM).
2024 · Eduardo Terán Brage, Jorge Feito Pérez, et al. · Journal of Clinical Oncology
Abstract P4-07-08: IMPACT ON OVERALL SURVIVAL ACCORDING TO BREAST CANCER IMMUNOPHENOTYPES: REAL-WORLD DATA IN METASTATIC BREAST CANCER IN ECUADOR
2023 · Evelyn Valencia-Espinoza, Emiliano Pulla-Cadmilema, et al. · Cancer Research
Abstract P4-07-07: Impact on overall survival according to sites of metastasis: Real-world data
2023 · Lissette Yagual Bohorquez, Evelyn Valencia-Espinoza, et al. · Cancer Research
Abstract P4-07-64: Impact of baseline ECOG, comorbidities, and surgery treatment election on overall survival
2023 · Elina A. Rodriguez-Melendez, Emiliano Pulla-Cadmilema, et al. · Cancer Research
1003P Expression by immunohistochemistry of p53 tumor suppressor protein as a predictive biomarker of response to immune checkpoint inhibitors in non-small cell lung cancer
2021 · A. Olivares Hernandez, E. del Barco, et al. · Annals of Oncology
PDF
Works count: 36
Citation count: 148
H-index: 7
I10-index: 6
Year
Topic
Type